Expected Cost of Oxford COVID-19 Vaccine in India

Saturday, 25 Jul, 2020

CM sought his cooperation to keep Odisha as a priority for vaccination once necessary clearances are obtained. Women with no pregnancy will also be selected for the trial in the first phase.

New Delhi: The first phase of the human trial of "COVAXIN", the country's first indigenously developed vaccine for the prevention of coronavirus, has started in AIIMS on Friday.

The Imperial vaccine is based on a new approach that uses synthetic strands of genetic code (called RNA), based on the virus's genetic material.

The WHO added that additional doses would be made available based on the country's needs and vulnerability, and the threat of Covid-19.

The WHO noted that the goal of COVAX is to deliver two billion doses of safe, effective, vaccines by the end of 2021. Frank Pallone, D-N.J., said he was anxious Trump could push the agency into prematurely clearing a vaccine.

The bloc is now in talks with several drugmakers to secure in advance their potential vaccines against the coronavirus, officials told last week.

His father and company chairman Cyrus Poonawalla had on Tuesday said SII is aiming to sell the vaccine for under Rs 1,000 per dose in India.

If COVID-19 vaccines prove effective in trials they are unlikely to be immediately available in large amounts. The Serum Institute of India (SII) has tied up with the Oxford-AstraZeneca vaccine to manufacture two-three million doses of vaccine by end-August. A shot of the Covaxin vaccine was given to a healthy 30-year-old male. Andrew Pollard, an Oxford Professor, was quoted saying that the antibody and T-cell responses are the two distinct ways in which the human immune system finds and attacks pathogens.

The Government said the centre, bought from Benchmark Holdings, will have the capacity to produce millions of doses a month, ensuring the United Kingdom has the capabilities to manufacture vaccines and advanced medicines, including for emerging diseases, far into the future.

Regulators that normally work within their own countries or regions will likely harmonize efforts on potential COVID-19 vaccines to speed up their approvals once they become available, World Health Organization chief scientist Soumya Swaminathan said on Friday.

The Oxford candidate, along with the Chinese and American biotech, Moderna candidates, represent rising hope that scientists are getting closer to a vaccine that would defeat the coronavirus.

Doing so will increase the UK's ability to respond to diseases like coronavirus and to prepare for potential future pandemics while creating new, high-skilled jobs to fuel the UK's economic recovery. Bulk development of this vaccine will also begin in September.

Farrar also lashed the government for having lockdown too late as it should have been ordered earlier.